Dornase Alpha Versus Hypertonic Saline for Lung Atelectasis in Non-Cystic Fibrosis Patients
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
Despite the lack of trials proving the efficacy of DNase in non cystic fibrosis patients, it
is currently heavily used in this population. In fact, per evidence of barcode scanning via
Meditech computer system at OU Medical Center 93% of the DNase prescribed in 2005 was for non
Cystic fibrosis patients with an estimated yearly cost of $341,968.15.In vitro studies showed
that the effect of Dnase was minimal on sputum viscosity when compared to Hypertonic saline .
Furthermore recent studies on hypertonic saline in cystic fibrosis patients showed that it is
an inexpensive and safe therapy when preceded by a bronchodilator in patients with cystic
fibrosis.
We hereby propose a prospective randomized trial to compare the efficacy of hypertonic
saline, DNase, vs. normal saline in the treatment of atelectasis in non cystic fibrosis,
mechanically ventilated patient.